MD809B2 - (-)-Enantiomer cis-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1H)- pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer si (+)-enantiomer, procedeu de obtinere a lor, compozitie antivirotica si procedeu de tratament al mamiferelor, inclusiv al omului, ce sufera de infectii virotice sau sunt susceptibile fata de aceste infectii - Google Patents

(-)-Enantiomer cis-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1H)- pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer si (+)-enantiomer, procedeu de obtinere a lor, compozitie antivirotica si procedeu de tratament al mamiferelor, inclusiv al omului, ce sufera de infectii virotice sau sunt susceptibile fata de aceste infectii

Info

Publication number
MD809B2
MD809B2 MD94-0298A MD940298A MD809B2 MD 809 B2 MD809 B2 MD 809B2 MD 940298 A MD940298 A MD 940298A MD 809 B2 MD809 B2 MD 809B2
Authority
MD
Moldova
Prior art keywords
hydroxymethil
oxathiolan
amino
enantiomer cis
enantiomer
Prior art date
Application number
MD94-0298A
Other languages
English (en)
Other versions
MD809C2 (ro
Inventor
Pharma Incorporated Biochem
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10675345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD809(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of MD809B2 publication Critical patent/MD809B2/ro
Publication of MD809C2 publication Critical patent/MD809C2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MD94-0298A 1990-05-02 1991-05-02 (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii MD809C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909009861A GB9009861D0 (en) 1990-05-02 1990-05-02 Chemical compounds
PCT/GB1991/000706 WO1991017159A1 (en) 1990-05-02 1991-05-02 1,3-oxathiolane nucleoside analogues

Publications (2)

Publication Number Publication Date
MD809B2 true MD809B2 (ro) 1997-08-31
MD809C2 MD809C2 (ro) 1998-07-31

Family

ID=10675345

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0298A MD809C2 (ro) 1990-05-02 1991-05-02 (-)-Enantiomer cis-4-amino-1-(2-hidroximetil -1,3-oxatiolan-5-il)-(1H)-pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer şi (Ş)-enantiomer, procedeu de obţinere a lor, compoziţie antivirotică şi procedeu de tratament al mamiferelor, inclusiv al omului, ce suferă de infecţii virotice sau sunt susceptibile faţă de aceste infecţii

Country Status (35)

Country Link
US (3) US6180639B1 (ro)
EP (2) EP0625150A1 (ro)
JP (3) JP2927546B2 (ro)
KR (1) KR960007532B1 (ro)
CN (3) CN1036196C (ro)
AP (1) AP182A (ro)
BG (1) BG60679B1 (ro)
CA (2) CA2059263C (ro)
CZ (1) CZ288499B6 (ro)
EG (1) EG19958A (ro)
FI (1) FI111722B (ro)
GB (1) GB9009861D0 (ro)
GE (1) GEP19991705B (ro)
HK (1) HK1043940B (ro)
HU (2) HUT64335A (ro)
IE (1) IE911482A1 (ro)
IL (1) IL98025A (ro)
MA (1) MA22144A1 (ro)
MD (1) MD809C2 (ro)
MY (1) MY109796A (ro)
NO (1) NO180377B (ro)
NZ (1) NZ238017A (ro)
OA (1) OA09559A (ro)
PL (1) PL167682B1 (ro)
PT (1) PT97520B (ro)
RO (1) RO112616B1 (ro)
RU (1) RU2099338C1 (ro)
SG (1) SG46383A1 (ro)
SK (1) SK283430B6 (ro)
TN (1) TNSN91029A1 (ro)
TW (2) TW366346B (ro)
UA (1) UA40589C2 (ro)
WO (1) WO1991017159A1 (ro)
YU (1) YU78291A (ro)
ZA (1) ZA913293B (ro)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
PT674634E (pt) * 1989-02-08 2003-09-30 Iaf Biochem Int Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
GB9215176D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
IT1290447B1 (it) * 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
RU2439069C2 (ru) 1998-08-12 2012-01-10 Гайлид Сайенсиз, Инк. Способ получения 1,3-оксатиолановых нуклеозидов
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ATE287268T1 (de) 1998-11-02 2005-02-15 Gilead Sciences Inc Kombinationstherapie zur behandlung von hepatitis b infektionen
JP2002533470A (ja) 1998-12-23 2002-10-08 シャイアー・バイオケム・インコーポレイテッド 抗ウイルス性ヌクレオシド類似体
GB9909154D0 (en) * 1999-04-22 1999-06-16 Nippon Glaxo Limited Pharmaceutical formulation
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2690137C (en) 2001-03-01 2012-11-13 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US6649607B2 (en) 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
CN1585631A (zh) * 2001-11-02 2005-02-23 桑多斯公司 制备快速溶解的高填量利巴韦林组合物的方法
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CA2505130C (en) * 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
FR2855822B1 (fr) * 2003-06-05 2005-07-22 Univ Grenoble 1 Acides nucleiques en tant que nouveaux selecteurs chiraux specifiques
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
LV13544B (en) 2005-08-15 2007-05-20 Grindeks As Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
JP5184511B2 (ja) 2006-04-18 2013-04-17 ルピン・リミテッド 新しい結晶形態のラミブジン
US20100196273A1 (en) * 2007-02-12 2010-08-05 Board Of Regents, University Of Texas System Novel agent for in vivo pet imaging of tumor proliferation
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
WO2009069011A1 (en) 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Process for the preparation of substituted 1,3-oxathiolanes
EP2222311B1 (en) * 2007-12-20 2013-03-27 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
EP2318398A4 (en) 2008-09-01 2011-12-07 Hetero Research Foundation PROCESS FOR PREPARING A POLYMORPHIC FORM OF LAMIVUDIN
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
WO2010082128A1 (en) 2009-01-19 2010-07-22 Aurobindo Pharma Limited Process for the preparation of cis-nucleoside derivative
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
CA2789078A1 (en) 2010-02-12 2011-08-18 Merck Sharp & Dohme Corp. Preparation of lamivudine form i
CN102167696B (zh) 2010-02-25 2013-09-18 南京正大天晴制药有限公司 拉米夫定草酸盐及其制备方法
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102234269B (zh) * 2010-04-29 2015-09-16 重庆医药工业研究院有限责任公司 拉米夫定的工业化制备方法
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN103315963A (zh) * 2013-06-21 2013-09-25 北京阜康仁生物制药科技有限公司 一种稳定的拉米夫定颗粒剂
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
JPS5668674A (en) 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
IT1212737B (it) * 1983-05-06 1989-11-30 Daniele Gatti Derivati pirimidinici ad azione antivirale.
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
DE3529263A1 (de) 1985-08-16 1987-02-19 Hoechst Ag Verfahren zur herstellung von 2-oxo-1,3-dioxolanen
CA1327000C (en) 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US4997926A (en) 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE3827134A1 (de) 1988-08-10 1990-03-15 Bayer Ag Substituierte triazolyl- bzw. imidazolyl-hydroxyalkyldioxolane, verfahren zu ihrer herstellung und ihre verwendung als mikrobizide, oxiranyldioxolane, dioxolanylketone, oxiranylketone und (alpha)-halogenketone als zwischenprodukte und verfahren zu deren herstellung
NZ233197A (en) 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
DE69033252T2 (de) 1989-06-27 1999-12-09 The Wellcome Foundation Ltd., Greenford Therapeutische nukleoside
IE902574A1 (en) 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
IE74701B1 (en) 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
US5039567A (en) 1989-12-04 1991-08-13 Supracor Systems, Inc. Resilient panel having anisotropic flexing characteristics and method of making same
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DK0513917T4 (da) 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides

Also Published As

Publication number Publication date
JP2927546B2 (ja) 1999-07-28
SK283430B6 (sk) 2003-07-01
IL98025A0 (en) 1992-06-21
RO112616B1 (ro) 1997-11-28
CN1326743A (zh) 2001-12-19
MY109796A (en) 1997-07-30
NO920018L (no) 1992-01-02
NO920018D0 (no) 1992-01-02
WO1991017159A1 (en) 1991-11-14
US6180639B1 (en) 2001-01-30
TNSN91029A1 (fr) 1992-10-25
EP1062950A3 (en) 2003-05-02
KR960007532B1 (ko) 1996-06-05
EP0625150A1 (en) 1994-11-23
SG46383A1 (en) 1998-02-20
EG19958A (en) 1996-10-31
MD809C2 (ro) 1998-07-31
AP182A (en) 1992-06-30
GB9009861D0 (en) 1990-06-27
HU210803A9 (en) 1995-07-28
AU7771991A (en) 1991-11-27
PL293181A1 (ro) 1993-02-08
RU2099338C1 (ru) 1997-12-20
ZA913293B (en) 1992-02-26
CA2337748A1 (en) 1991-11-14
CZ288499B6 (en) 2001-06-13
TWI222448B (en) 2004-10-21
HK1043940B (zh) 2005-03-24
US20030004175A1 (en) 2003-01-02
IE911482A1 (en) 1991-11-06
PL167682B1 (pl) 1995-10-31
HU9200302D0 (en) 1992-04-28
CN1108655A (zh) 1995-09-20
PT97520A (pt) 1992-01-31
BG95705A (bg) 1993-12-24
CS125191A3 (en) 1992-01-15
CN1058214A (zh) 1992-01-29
JP2000128787A (ja) 2000-05-09
FI111722B (fi) 2003-09-15
CA2059263C (en) 2001-04-10
HK1043940A1 (en) 2002-10-04
AP9100255A0 (en) 1991-07-31
YU78291A (sh) 1994-06-10
MA22144A1 (fr) 1991-12-31
HUT64335A (en) 1993-12-28
CN1056145C (zh) 2000-09-06
UA40589C2 (uk) 2001-08-15
BG60679B1 (bg) 1995-12-29
NZ238017A (en) 1994-06-27
KR920702682A (ko) 1992-10-06
JPH1180153A (ja) 1999-03-26
CN1036196C (zh) 1997-10-22
GEP19991705B (en) 1999-08-05
OA09559A (fr) 1993-01-31
PT97520B (pt) 1998-08-31
TW366346B (en) 1999-08-11
IL98025A (en) 1996-10-16
JPH05501117A (ja) 1993-03-04
JP3062475B2 (ja) 2000-07-10
CN1154500C (zh) 2004-06-23
FI916165A0 (fi) 1991-12-30
US20050250950A1 (en) 2005-11-10
CA2059263A1 (en) 1991-11-03
EP1062950A2 (en) 2000-12-27
NO180377B (no) 1996-12-30
AU651345B2 (en) 1994-07-21

Similar Documents

Publication Publication Date Title
MD809B2 (ro) (-)-Enantiomer cis-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1H)- pirimidin-2-on sau sarea lui, sau esterul lui, sau sarea esterului lui, amestec de (-)-enantiomer si (+)-enantiomer, procedeu de obtinere a lor, compozitie antivirotica si procedeu de tratament al mamiferelor, inclusiv al omului, ce sufera de infectii virotice sau sunt susceptibile fata de aceste infectii
EP0456063A3 (en) 1-h-3-aryl-pyrrolidin-2,4-dion-derivatives
DE69107059D1 (en) Sigma-delta-modulator.
AR244753A1 (es) Azocolorantes.
CY2036A (en) Substitued-1,3-oxathiolanes with antiviral properties
ZA919797B (en) Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
ZA919660B (en) Alpha-oxoacetamide derivatives.
PH30977A (en) Hiv-inhibiting benzene-acetamide derivatives.
DE69104185D1 (en) Luftreservoir.
DE69111595D1 (en) Squarylium- und crokonyliumfarbstoffe.
DE69106281D1 (en) Phenanthrenderivat.
FI930881A (fi) Foerarhytt, speciellt foer terraengfordon
DE69102074D1 (en) Thermographische elemente.
DE69102644D1 (en) Demodulationsreferenzsignalquelle.
DE69114491D1 (en) Olefincopolymere.
DE59102290D1 (en) Thermo-fixierstation mit bandtransport.
EP0481950A3 (en) 1,4-dideoxy-4-fluoronojirimycin
DE4092638D2 (en) Mappe, insbesondere muster-, werbe- oder angebotsmappe
DE59100097D1 (en) Plungerzylinder.
DE69100445D1 (en) Thiosulfatfixierloesungen.
GB9024371D0 (en) Putting,perceptor
IE900821L (en) 3-keto-16ó,17ó-dihydroxysteroids
FI932808A (fi) Kaernreaktorelement, isynnerhet styrelement
ZA916783B (en) Indolonaphthyridines.
IE900859L (en) Azole-1-alkanamides.

Legal Events

Date Code Title Description
FG4A Patent for invention issued
IF99 Valid patent on 19990615

Free format text: EXPIRES: 20110502

TC4A Change of name of proprietor (patent for invention)

Owner name: SHIRE BIOCHEM INC., CA; 2250, BOUL. ALFRED-NOBEL B

Free format text: PREVIOUS NAME OF PROPRIETOR: BIOCHEM PHARMA INC., CA; 275 ARMAND-FRAPPIER BOULEVARD LAVAL, QUEBEC, CANADA H7V 4A7 (CA)

TC4A Change of name of proprietor (patent for invention)

Owner name: SHIRE CANADA INC, CA; 2250, BOUL. ALFRED-NOBEL BUR

Free format text: PREVIOUS NAME OF PROPRIETOR: SHIRE BIOCHEM INC., CA; 2250, BOUL. ALFRED-NOBEL BUR. 500 VILLE SAINT-LAURENT QUEBEC H4S 2C9

MK4A Patent for invention expired